Glenview's Robbins says talk of Amazon's entering pharma is overblown

Reuters  |  NEW YORK 

(Reuters) - Capital Management said on Monday at the Sohn Conference in that he still likes a trio of stocks he already owns, citing Corp , McKesson Corp and Holdings .

He also said speculation that might be looking to enter the pharmacy business and possibly threaten these companies' business is overblown.

Amazon has not made significant hires in the pharmacy business and does not have the licenses needed to enter the business, said. Amazon's entry into the business of selling medications, is "neither imminent, assured, nor likely to succeed," he said.

Speculation mounted late last year that the might be ready to target pharmacies and the selling of drugs next after buying grocer earlier in 2017.

The speculation about Amazon has weighed on CVS's stock price. But was confident his stock picks could rise.

Within two year, said, Express Scripts' stock could climb 69 percent while McKesson's stock could post returns of 136 percent and CVS could climb 96 percent. "Amazon fears are dramatically overblown," he said.

(Reporting by and Svea Herbst-Bayliss; Editing by Leslie Adler)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, April 24 2018. 03:24 IST